Oyavas (Bevacizumab)

Bevacizumab, the active ingredient in Oyavas, is a monoclonal antibody presented as a 100 mg/4 ml solution for intravenous use. It is employed in the treatment of various solid tumours and ocular neovascular conditions in adult patients.

GNH USA supplies Oyavas as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialised clinics worldwide.

Bevacizumab acts on vascular endothelial growth factor pathways that drive abnormal angiogenesis in several disease states. - Metastatic colorectal cancer: improves survival when combined with chemotherapy. - Non‑small cell lung cancer: used with chemotherapy to enhance response rates. - Age‑related macular degeneration: administered intravitreally to reduce vision loss. - Glioblastoma multiforme: used as part of multim‑modal therapy to prolong progression‑free survival. - Ovarian cancer: combined with carb‑‑  

Bevacizumab ...